{
  "eval_id": "S16",
  "eval_file": "evals/single/S16.json",
  "timestamp": "2025-09-18T17:14:06.241046+00:00",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with ER-positive, HER2-negative advanced breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor where appropriate. Efficacy and safety are based on the TROPiCS-02 study; please refer to the EMA SmPC for full details. If youâ€™d like, send me the SmPC citation by email for my records."
}